About this trial
This study is looking at cord blood transplants (CBT) for adults with blood cancers. It focuses on how to optimize this treatment to improve outcomes. The goal is to gather information on participant experiences after receiving CBT, including side effects and how well the treatment works. The cancers included are various types of leukemia and lymphoma.
This is a Phase 2 trial, which means it's looking at how well the treatment works and how safe it is. The trial is FDA-regulated and aims to include about 54 participants.
Who can join
Adults aged 21 to 65 years can join this study. It is open to both men and women with specific types of high-risk blood cancers. Participants must meet certain health and treatment criteria, which the trial team will confirm.
Conditions
Acute Myelogenous Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Chronic Myelogenous Leukemia (CML), Myelodysplastic Syndromes (MDS), Myeloproliferative Disorder, Non-Hodgkin's Lymphoma
Age group
Adult, Older adult
The study team makes the final call on eligibility.
What happens in the study
Everyone in the study will receive a cord blood transplant. They will undergo assessment to see if they qualify. Patients will receive standard conditioning treatments to prepare their bodies. The transplant will use a double-unit cord blood graft, following specific guidelines.
Where
This trial is running at 1 location in the United States. It is currently recruiting.
Memorial Sloan Kettering Cancer Center
New York, New York